Assurance report on Hvsen Biotechnology Co.Ltd(300871) investment projects invested with raised funds in advance with self raised funds
Zhonghuan zhuanzi (2022) No. 0100007 Hvsen Biotechnology Co.Ltd(300871) board of directors:
We accept the entrustment that Hvsen Biotechnology Co.Ltd(300871) (hereinafter referred to as ” Hvsen Biotechnology Co.Ltd(300871) “) as of December 31, 2021, The assurance work was carried out in the report on the investment projects with raised funds (hereinafter referred to as the “investment projects with raised funds”) contained in the prospectus for the issuance of convertible corporate bonds on the Hvsen Biotechnology Co.Ltd(300871) gem to unspecified objects signed on December 14, 2021 (hereinafter referred to as the “Report on the investment projects with raised funds in advance”).
In accordance with the relevant requirements of the guidelines for self discipline supervision of listed companies of Shenzhen Stock Exchange No. 2 – standardized operation of companies listed on the gem issued by Shenzhen Stock Exchange, prepare the report on the investment projects invested with raised funds in advance with self raised funds, and ensure that its contents are true, accurate and complete without false records, misleading statements or major omissions, It is the responsibility of the Hvsen Biotechnology Co.Ltd(300871) board of directors to provide true, legal and complete physical evidence, original written materials, duplicate materials, oral testimony and other evidence we deem necessary for our assurance work. Our responsibility is to express assurance opinions on the report on the investment projects invested with raised funds in advance with self raised funds on the basis of the implementation of assurance work.
We have carried out the assurance work in accordance with the provisions of other assurance business standards for Chinese certified public accountants No. 3101 – assurance business other than audit or review of historical financial information, which requires us to abide by the code of professional ethics for Chinese certified public accountants, plan and perform the assurance work, To obtain reasonable assurance on whether there is no material misstatement in the report on the investment projects invested with raised funds in advance with self raised funds. In the assurance process, we implement understanding, inquiry, inspection, recalculation and work procedures that we deem necessary. We believe that our assurance work provides a reasonable basis for giving assurance opinions.
We believe that the above report on the investment projects invested with raised funds in advance with self raised funds has been prepared in accordance with the relevant requirements of the self regulatory guidelines for listed companies of Shenzhen Stock Exchange No. 2 – standardized operation of companies listed on GEM issued by Shenzhen Stock Exchange, In all major aspects, it truthfully reflects the situation that Hvsen Biotechnology Co.Ltd(300871) invested in the project with raised funds in advance with self raised funds.
This assurance report is only Hvsen Biotechnology Co.Ltd(300871) used for the reference purpose of replacing the self raised funds invested in the raised funds investment project in advance with the raised funds, and shall not be used for any other purpose.
Zhongshen Zhonghuan Certified Public Accountants (special general partnership) Chinese Certified Public Accountants:
Luo Mingguo
Chinese certified public accountant:
Liu Xiaoying
Wuhan, China January 21, 2022
Hvsen Biotechnology Co.Ltd(300871)
Report on investment projects invested with raised funds in advance with self raised funds
According to the guidelines for the supervision of listed companies No. 2 – regulatory requirements for the management and use of raised funds by listed companies (revised in 2022) and the guidelines for the self-discipline supervision of listed companies on Shenzhen Stock Exchange No. 2 – standardized operation of companies listed on GEM issued by China Securities Regulatory Commission, and According to the relevant provisions of the guidelines for self discipline supervision of companies listed on the growth enterprise market of Shenzhen Stock Exchange No. 2 – announcement format No. 20: Announcement format for early investment in replacement of raised funds by listed companies, Hvsen Biotechnology Co.Ltd(300871) (hereinafter referred to as “the company”) pre invests raised funds into raised projects with self raised funds as follows:
1、 Basic information of raised funds
The company issued 7 million convertible corporate bonds to unspecified objects with a face value of 100 yuan each, which was approved by the reply on Approving the registration of Hvsen Biotechnology Co.Ltd(300871) issuing convertible corporate bonds to unspecified objects (zjxk [2021] No. 3570) issued by the China Securities Regulatory Commission on November 23, 2021, The total amount of funds raised is RMB 700 million.00 (in words: RMB 700 million). After deducting the underwriting recommendation fee of RMB 8556603.77 (excluding tax) from the issuance of convertible corporate bonds to unspecified objects (hereinafter referred to as “this issuance”), the raised funds of RMB 691443396.23 were transferred to the special storage account of raised funds designated by the company on December 23, 2021. The transfer of the above raised funds has been completed, and the raised funds have been verified by Zhongshen Zhonghuan Certified Public Accountants (special general partnership) and a verification report of Zhonghuan Yanzi (2021) No. 010097 has been issued.
Before the funds raised by this offering are received, the company will invest the raised investment projects in advance with self raised funds according to the actual progress of the raised investment projects. In addition, the company paid part of the issuance expenses with self raised funds before the arrival of the raised funds.
2、 Commitments of investment projects with raised funds
According to the company’s prospectus for issuing convertible corporate bonds to unspecified objects on the Hvsen Biotechnology Co.Ltd(300871) gem, the investment projects and use plans of the raised funds are as follows (amount unit: RMB 10000):
Project name total investment raised fund project filing or approval number total investment
1. Expansion project of tylosin production line with an annual output of 1000 tons and tylosin production line with an annual output of 600 33324.08 28500.00 2101-420981-04-01-383623 tons
Assurance report page 3 of 5
Project name total investment raised fund project filing or approval number total investment
2 Hubei Huisheng preparation production line automation comprehensive 13882.07 12100.00 2105-420981-04-02-687353 reconstruction and expansion project
3 pet preparation comprehensive production line construction project 9996.92 9000.00 2105-420981-04-01-485865 4 powder / premix production line expansion project 6358.05 4900.00 2105-420112-04-02-393559 5 supplementary working capital 15500.00 15500.00-
Total 79061.12 70000.00-
3、 Investment projects invested with raised funds in advance with self raised funds
The total amount of funds invested in advance is 142257508.94 yuan, including 140207469.46 yuan invested in the raised project with self raised funds and 2050039.48 yuan (excluding value-added tax) paid in advance with self raised funds.
(I) advance investment of self raised funds into projects invested with raised funds
In order to smoothly promote the construction of the company’s raised investment projects in this issuance, before the raised funds are in place, the company has invested the raised funds in advance according to the actual situation of the project progress. As of December 31, 2021, the cumulative amount of the company’s pre invested projects with self raised funds is 140207469.46 yuan. Therefore, the amount of the pre invested projects with raised funds that can be replaced by the raised funds this time is 140207469.46 yuan. The details are as follows (amount unit: RMB 10000 yuan):
Sequence project name raised funds self raised funds investment proposed replacement amount No. total input amount
1. Expansion project of tylosin production line with an annual output of 1000 tons and tylosin production line with an annual output of 600 tons
2 Hubei Huisheng preparation production line automation comprehensive reconstruction and expansion 12100.00 6815.64 6815.64 project
3 pet preparation comprehensive production line construction project 9000.00 370.75 370.75 4 powder / premix production line expansion project 4900.00 580.66 580.66 5 supplementary working capital 15500.00
Total 70000.00 14020.75 14020.75
(II) advance payment of issuance fees for self raised funds
Assurance report page 4 of 5
According to the verification report of Zhong Huan Yan Zi (2021) No. 0100097 issued by Zhong Shen Zhong Huan Certified Public Accountants (special general partnership), the issuance expenses of convertible corporate bonds issued by the company to unspecified objects amounted to 10700982.87 yuan (excluding value-added tax), of which the underwriting recommendation fee was 8556603.77 yuan (excluding value-added tax), It has been directly deducted from the raised funds. As of December 31, 2021, the amount of issuance expenses paid by the company with self raised funds is 2050039.48 yuan (excluding value-added tax), and the replacement issuance expenses are 2050039.48 yuan (excluding value-added tax).
4、 Implementation of replacement of pre investment with raised funds
According to the prospectus, the company has made arrangements for the replacement of raised funds in advance:
“If the actual raised funds (after deducting the issuance expenses) are less than the total amount of the proposed raised funds, the board of directors of the company will arrange the specific use of the raised funds according to the importance and urgency of the purpose of the raised funds, and the insufficient part will be solved by self financing.
Before the funds raised by issuing convertible bonds to unspecified objects are in place, if the company invests its own funds in the construction of the above projects, the company will replace them in accordance with the procedures specified in relevant laws and regulations after the raised funds are in place.
Within the final scope of the project invested by raising funds (subject to the documents filed by the relevant competent authorities), the board of directors of the company may appropriately adjust the specific arrangements such as the investment sequence and amount of the raised funds of the above projects according to the actual needs of the project. ” 5、 Examination and approval of replacing self raised funds invested in projects with raised funds in advance
The company’s self raised funds for the investment projects invested with raised funds in advance were reviewed and approved at the 22nd Meeting of the second board of directors of the company on January 21, 2022.
Hvsen Biotechnology Co.Ltd(300871)
January 21, 2022
Assurance report page 5 of 5
